CREATE Medicines Inc. (formerly Myeloid Therapeutics), a biotechnology company advancing in vivo immune-cell programming with ...

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from MAIA ...

The HSV-1 vector is currently being evaluated in a randomized placebo-controlled trial for the treatment of neurotrophic keratitis (NK), a rare degenerative corneal disease. The FDA’s platform ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ajooni Biotech Limited ( (IN:AJOONI)) has ...

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech ...

Applications are invited for recruitment of various technical positions or jobs in TRIHMS Naharlagun Arunachal Pradesh in 2025. Tomo Riba Inst ...

BSc Syllabus 2025: The Bachelor of Science (BSc) is a fundamental undergraduate degree program intended to expand students' horizons intellectually and strengthen their grasp of numerous scientific ...

Novo Nordisk, the Danish drug manufacturer behind the weight-loss and diabetes drug Ozempic and other medications, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with ...

World’s biggest tech and AI event returns across Dubai World Trade Centre The 2025 edition will bring together more than 6,800 companies and 2,000 startups from 180 countries in its biggest outing yet ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...